News
ESSENCE trial of Novo Nordisk's GLP-1 drug semaglutide shows efficacy in MASH, setting up filings in the US and Europe next year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback